Increased cerebrospinal fluid aβ38/aβ42 ratio in alzheimer disease

Neurodegenerative Diseases

Volumn 2, Issue 5, 2006, Pages 242-245

  Mehta, Pankaj D ^a   Pirttila, Tuula ^b  

^a NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Alzheimer disease, cerebrospinal fluid; Amyloid 1 38; Amyloid 1 40; Amyloid 1 42; Enzyme linked immunosorbent assay

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-38]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; QUANTITATIVE ANALYSIS;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEINS E; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; REFERENCE VALUES;

EID: 33744503967     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000090363     Document Type: Article

References (14)

1. Citron M: Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 2004;5:677-685.
2. Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, Eikenberg O, Antz C, Krause W, Reulbach U, Kornhuber J, Wiltfang J: Neurochemical diagnosis of Alzheimer's dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau. Neurobiol Aging 2004;25:273-281.
3. 1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 2004;9:705-710.
4. Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, Schmidt B, Klafki HW, Maler M, Dyrks T, Bienert M, Beyermann M, Rüther E, Kornhuber J: Highly conserved and disease-specific patterns of carboxyterminally truncated Aβ peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J Neurochem 2002;81:481-496.
5. Schoonenboom NS, Mulder C, Van Kamp GJ, Mehta SP, Scheltens P, Blankenstein MA, Mehta PD: Amyloid β 38, 40, and 42 species in cerebrospinal fluid: more of the same? Ann Neurol 2005;58:139-142.
6. Lewczuk P, Esselmann H, Bibl M, Sabine P, Svitek J, Miertschischk J, Meyrer R, Smirnov A, Maler JM, Klein C, Otto M, Bleich S, Sperling W, Kornhuber J, Rüther E, Wiltfang J: Electrophoretic separation of amyloid β peptides in plasma. Electrophoresis 2004;25:3336-3343.
7. Potempska A, Mack K, Mehta P, Kim KS, Miller DL: Quantification of sub-femtomole amounts of Alzheimer amyloid β peptides. Amyloid 1999;6:14-21.
8. Mehta PD, Mehta SP, Fedor B, Patrick BA, Emmerling M, Dalton AJ: Plasma amyloid β protein 1-42 levels are increased in old Down syndrome but not in young Down syndrome. Neurosci Lett 2003;342:155-158.
9. Kunicki S, Richardson J, Mehta PD, Kim KS, Zorychta E: The effects of age, apolipoprotein E phenotype and gender on the concentration of amyloid-β (Aβ) 40, Aβ42, apolipoprotein E and transthyretin in human cerebrospinal fluid. Clin Biochem 1998;31:409-412.
10. Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, Sasaki H, Abe K, Iwatsubo T, Kosaka T, Watanabe M, Tomidokoro Y, Shizuka M, Mizushima K, Nakamura T, Igeta Y, Ikeda Y, Amari M, Kawarabayashi T, Ishiguro K, Harigaya Y, Wakabayashi K, Okamoto K, Hirai S, Shoji M: Longitudinal study of cerebrospinal fluid levels of tau, Abeta 1-40, and Abeta 1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 1998;44:17-26.
11. Mayeux R, Honig LS, Tang M-X, Manly J, Stern Y, Schupf N, Mehta PD: Plasma Aβ40 and Aβ42 and Alzheimer's disease: relation to age, mortality and risk. Neurology 2003;61:1185-1190.
12. Mehta PD, Pirttila T, Patrick BA, Barshatzky M, Mehta SP: Amyloid β protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett 2001;304:102-106.
13. Kuo Y-M, Kokjohn TA, Kalback W, Luehrs D, Galasko DR, Chevallier N, Koo EH, Emmerling MR, Roher AE: Amyloid-β peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. Biochem Biophys Res Commun 2000;268:750-756.
14. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH: A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 2001;414:212-216.